Navigation Links
Statistical Bowl - How the '07 Patriots and the '72 Dolphins Match Up
Date:1/30/2008

PHOENIX, Jan. 30 /PRNewswire/ -- Sports pundits across the country have been comparing the so-far unbeaten 2007 New England Patriots to the perfect 1972 Dolphins all year. Now, a New York cardiologist is using the scientific statistics used in large-scale medical trials to determine which of the two teams is superior.

Using a format and approach typically reserved for the cardiovascular therapy studies he writes and reviews, Dr. Jonathan Sackner-Bernstein, a Food & Drug Administration advisor and the Chief Medical Officer at Clinilabs, a clinical research organization in New York, compares the 2007 New England Patriots and the 1972 Miami Dolphins.

Sackner-Bernstein was able to draw conclusions by analyzing the two teams' performance relative to their peers in categories that reflect their relative dominance: total offensive and defensive points and yards. Game-by-game performance for the 2007 Patriots and 1972 Dolphins was adjusted to be relative to all of the games played in each respective year, and then those results were compared directly. In statistical terms, the performance statistics were normalized to the median values. A second analysis further adjusted the two for the basis of comparison, by using the opponents' winning percentage to normalize the scores and yardage.

Sackner-Bernstein's data showed a statistical trend in favor of the Patriots as the better offensive team, scoring more than a touchdown more per game than the Dolphins. However, to counteract the offensive prowess of the Patriots, the '72 Dolphins defense gave up 50 percent fewer points than the '07 Patriots, giving the Dolphins a slight edge. The teams both enjoyed greater net yardage than their opponents by almost the same amount ('07 Patriots +123 yards vs. '72 Dolphins +124 yards).

Using the jargon of medical science, none of the differences noted were statistically significant. In the end, the statistical data show that, provided the Patriots win the Super Bowl, there is no evidence of statistical superiority of either team over the other.

"As a lifelong Dolphins fan, I acknowledge that I was really hoping the data would show that the 1972 Dolphins were superior to the 2007 Patriots," said Dr. Sackner-Bernstein. "Unfortunately, this analysis of the data doesn't lie -- the only way for that to happen now is for the Giants to give the Patriots a notch in the loss column."

Dr. Sackner-Bernstein continued, "It is difficult to make a direct comparison between the two teams beyond the statistics that were analyzed. Players these days are not only bigger, stronger and faster, but there have been changes in the rules for blocking and pass defense that make direct comparisons between the two teams arbitrary."

The full statistical analysis of the '07 Patriots and '72 Dolphins is available to read and includes further insight into parameters, omitted statistics and additional notes of interest. As a cardiologist, Dr. Sackner-Bernstein has made his analysis available on a Web site for cardiovascular health care professionals, theheart.org, at http://www.theheart.org/article/840959.do.

About Dr. Sackner-Bernstein

Jonathan D. Sackner-Bernstein, M.D., F.A.C.C. is Chief Medical Officer of Clinical Research at Clinilabs (http://www.clinilabs.com), a clinical research organization focusing on central nervous system and cardiovascular therapeutics as well as therapies in early clinical development.

Dr. Sackner-Bernstein is an internationally recognized leader in the field of cardiology research. He is particularly known for his expertise in drug safety, which has impacted the design of clinical trials utilizing devices and pharmacologic therapies. Dr. Sackner-Bernstein serves as an advisor to the U.S. Food and Drug Administration's Cardiovascular and Renal Drug Advisory Committee and as an ad-hoc member of its advisory committee. Recently, Sackner-Bernstein was appointed a member of the Medical Devices Dispute Resolution Committee in FDA's Center for Devices and Radiologic Health. He also serves as a regulatory consultant for several firms to help them navigate study design and therapeutic safety for Phase I through Phase IV studies. Dr. Sackner-Bernstein is an active lecturer and visiting professor at leading medical centers around the country.

Media Contacts:

Jonathan Sackner-Bernstein, M.D.

jonathansb@yahoo.com

For interviews, please contact:

David Berry, MCS Public Relations

W: (800) 477-9626 x22

C: (908) 872-3777

davidb@mcspr.com


'/>"/>
SOURCE MCS Public Relations
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
2. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
3. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
4. Gleaners Community Food Bank Board Members Match Donations December 19, 2007
5. Marianjoy Rehabilitation Hospital Therapeutic Golf Program Receives a $20,000 Matching Grant From the USGA
6. S3 Matching Technologies Aids in Reducing Risk to Texas Medicaid System
7. Many prostate cancer patients receive improper or mismatched therapies
8. Mismatched prostate cancer treatment more common than expected
9. BCP Veterinary Pharmacy Helps Cure Diabetic Cats with BCP PZI(R), the Closest Match to Feline Insulin Available
10. Neurotechnologija Releases Smartcard Face-Match Add-on for the Implementation of Biometric Face-on-Smartcard Verification Systems
11. Gene Tests Match Up Lung Tumors, Best Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: